Perrigo Company PLC Stock TEL AVIV STOCK EXCHANGE
Equities
IE00BGH1M568
Pharmaceuticals
Sales 2024 * | 4.62B 1,664B | Sales 2025 * | 4.83B 1,739B | Capitalization | 3.75B 1,349B |
---|---|---|---|---|---|
Net income 2024 * | -74M -26.65B | Net income 2025 * | 103M 37.09B | EV / Sales 2024 * | 1.51 x |
Net Debt 2024 * | 3.21B 1,156B | Net Debt 2025 * | 3.01B 1,085B | EV / Sales 2025 * | 1.4 x |
P/E ratio 2024 * |
-19
x | P/E ratio 2025 * |
172
x | Employees | - |
Yield 2024 * |
4.01% | Yield 2025 * |
4.27% | Free-Float | 99.66% |
Latest transcript on Perrigo Company PLC
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 23-06-29 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 22-05-15 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 20-12-14 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 17-02-05 |
Bradley Alford
BRD | Director/Board Member | 67 | 17-02-05 |
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |